David H. Ilson
#148,673
Most Influential Person Now
David H. Ilson's AcademicInfluence.com Rankings
David H. Ilsonmedical Degrees
Medical
#2833
World Rank
#3273
Historical Rank
Oncology
#183
World Rank
#189
Historical Rank
David H. Ilsonphilosophy Degrees
Philosophy
#8116
World Rank
#11439
Historical Rank
Logic
#5149
World Rank
#6524
Historical Rank
Download Badge
Medical Philosophy
Why Is David H. Ilson Influential?
(Suggest an Edit or Addition)David H. Ilson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (576)
- Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology (2016) (544)
- Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. (2006) (405)
- Esophageal and esophagogastric junction cancers, version 1.2015. (2015) (396)
- Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face (1999) (390)
- Gastric Cancer, Version 2.2013 (2013) (364)
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (343)
- Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. (2003) (340)
- Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. (2013) (306)
- Esophageal and esophagogastric junction cancers. (2011) (276)
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. (2018) (267)
- Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. (1999) (254)
- Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer (1997) (246)
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (229)
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. (2018) (214)
- Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. (1998) (207)
- Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (203)
- Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. (2011) (189)
- American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. (2007) (176)
- Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. (1992) (169)
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. (2020) (167)
- Targeted therapies for esophageal cancer. (2005) (149)
- Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. (2019) (148)
- Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. (2015) (146)
- Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial (2017) (145)
- Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer (2001) (131)
- Preoperative 5‐fluorouracil, low‐dose leucovorin, and concurrent radiation therapy for rectal cancer (1994) (130)
- A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. (2000) (127)
- Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. (2005) (127)
- NCCN task force: clinical utility of PET in a variety of tumor types. (2009) (119)
- Optimal chemotherapy for advanced gastric cancer: is there a global consensus? (2014) (104)
- Clinical Relevance of the i(12p) Chromosome in Germ cell Tumors (1994) (103)
- Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. (2003) (100)
- Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. (2008) (99)
- Esophageal cancer chemotherapy: recent advances. (2008) (98)
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. (2018) (98)
- KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. (2019) (96)
- Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma (2011) (94)
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus (2011) (92)
- Advances in the treatment of gastric cancer (2017) (91)
- Post-treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal Cancer (2009) (91)
- Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma (2009) (84)
- Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. (2015) (82)
- Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. (2007) (77)
- A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. (2002) (74)
- Combined modality chemoradiation in elderly oesophageal cancer patients (2007) (71)
- CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. (2016) (70)
- Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer (2012) (67)
- Oesophageal cancer: new developments in systemic therapy. (2003) (66)
- Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. (2004) (65)
- A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. (1992) (63)
- Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. (2017) (62)
- Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. (2017) (61)
- Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer (2019) (60)
- Combined modality therapy in the treatment of esophageal cancer. (1994) (60)
- Esophagogastric cancer: targeted agents. (2010) (59)
- CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. (2010) (59)
- Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? (2007) (55)
- Patterns and Predictors of Weight Loss After Gastrectomy for Cancer (2016) (52)
- Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer (2008) (48)
- Clinical relevance of the i(12p) marker chromosome in germ cell tumors. (1994) (47)
- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. (2002) (47)
- Treatment of localized esophageal cancer. (2004) (46)
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). (2019) (46)
- Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. (1994) (44)
- Irinotecan in esophageal cancer. (2000) (43)
- European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. (2008) (43)
- Management of localized esophageal cancer in the older patient. (2014) (41)
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma (2011) (41)
- Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. (2004) (39)
- Angiogenesis in gastric cancer: hitting the target? (2014) (39)
- Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer (2015) (36)
- Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. (1993) (36)
- Advances in the treatment of gastric cancer (2017) (35)
- Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. (2006) (34)
- RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. (2014) (33)
- RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. (2018) (33)
- Esophageal and Esophagogastric Junction Cancers Clinical Practice Guidelines in Oncology (2011) (32)
- A phase II trial of interferon alpha‐2A, 5‐fluorouracil, and cisplatin in patients with advanced esophageal carcinoma (1995) (31)
- Prognostic Factors After Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus (2007) (31)
- Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. (2009) (31)
- Advances in the treatment of gastric cancer: 2019. (2019) (31)
- A phase II study of preoperative chemotherapy with irinotecan(CPT) and cisplatin(CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome (2007) (30)
- The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. (2014) (30)
- Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. (2014) (30)
- Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. (2018) (29)
- Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers (2014) (28)
- Esophageal Cancer Clinical Practice Guidelines. (2006) (27)
- Gastric Cancer Clinical Practice Guidelines. (2006) (27)
- Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma (2016) (27)
- Targeted agents and esophageal cancer--the next step? (2007) (26)
- A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer. (2013) (26)
- Management of esophageal cancer. (1996) (26)
- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease (2007) (25)
- Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer (2015) (25)
- Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer (2003) (25)
- Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). (2012) (24)
- Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. (2015) (24)
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial (2022) (22)
- The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. (2016) (22)
- A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2005) (22)
- Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial (2021) (22)
- Preoperative therapy for esophageal cancer. (2008) (21)
- Gastric cancer. (2010) (21)
- HER2 Directed Therapy for Gastric/Esophageal Cancers (2014) (21)
- Optimal management of gastroesophageal junction cancer (2019) (20)
- Phase II trial of topotecan in patients with advanced renal cell carcinoma (2004) (19)
- Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. (2013) (19)
- Irinotecan, cisplatin, and radiation in esophageal cancer. (2002) (19)
- Management of gastric cancer (2014) (18)
- Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. (2007) (18)
- New developments in the treatment of esophageal cancer (2002) (18)
- Volumetric 3D CT analysis - an early predictor of response to therapy (2007) (17)
- Combined modality therapy in esophageal cancer: the Memorial experience. (2003) (17)
- Phase II clinical trial of 13‐cis‐retinoic acid and interferon‐α‐2a in patients with advanced esophageal carcinoma (1999) (17)
- Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis. (2009) (16)
- Adjuvant treatment for gastric cancer: too much is not enough. (2014) (16)
- Cancer of the gastroesophageal junction: combined modality therapy. (2006) (16)
- Maintenance Olaparib for Germline (2019) (16)
- Genetic analysis of germ cell tumors: current progress and future prospects. (1991) (16)
- Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma (2012) (15)
- Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer (2008) (15)
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (2019) (15)
- Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS (2020) (15)
- Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). (2006) (15)
- NCCN Task Force (2009) (14)
- Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma (2015) (14)
- 741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA. (2014) (14)
- A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). (2015) (13)
- Esophageal Cancer: Adjuvant Therapy (2007) (13)
- Role of neoadjuvant therapy for esophageal adenocarcinoma. (2009) (13)
- Esophageal cancer. (2020) (12)
- Gastric Cancer, Version 2.2022 (2022) (12)
- Adjuvant therapy in colon cancer: less is more. (2018) (12)
- Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. (2016) (12)
- Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? (2002) (12)
- Current Progress in the Adjuvant Treatment of Gastric Cancer. (2017) (12)
- Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer (2018) (12)
- Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy (2019) (12)
- RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2013) (11)
- Positron‐Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron‐Emission Tomography Nonresponders (2019) (11)
- A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. (1997) (11)
- Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). (2018) (10)
- Cancer of the gastroesophageal junction: Current therapy options (2006) (10)
- Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy (2005) (10)
- SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study (2019) (10)
- Chemotherapeutic options for gastroesophageal junction tumors. (2013) (10)
- Adjuvant (postoperative) therapy for esophageal cancer. (2013) (10)
- Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. (2018) (10)
- Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence (2021) (10)
- Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients. (2017) (9)
- Genomic profiling of esophagogastric (EG) tumors in clinical practice. (2015) (9)
- Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword? (2007) (9)
- Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. (2012) (9)
- Pelvic CT in patients with esophageal cancer. (2005) (9)
- Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma. (2011) (9)
- Emerging tyrosine kinase inhibitors for esophageal cancer (2013) (9)
- Modern approaches to localized cancer of the esophagus. (2011) (9)
- Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. (2012) (9)
- Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer (2019) (9)
- The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery (2014) (9)
- Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan. (2010) (9)
- Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. (2019) (8)
- Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss? (2016) (8)
- Advances in the treatment of gastric cancer: 2020–2021 (2021) (8)
- Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer? (2018) (8)
- Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer (2014) (8)
- Chemotherapy in esophageal cancer. (1993) (8)
- Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer (2021) (8)
- Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study (2021) (8)
- Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma. (2010) (8)
- Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. (2016) (8)
- Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma. (2020) (7)
- Patient-derived xenografts as models for the identification of predictive biomarkers in esophagogastric cancer. (2014) (7)
- Successful treatment of esophageal cancer with airway invasion with induction chemotherapy and concurrent chemoradiotherapy. (2009) (7)
- Current and future therapies for targeting HER2 mutations in gastrointestinal cancer (2018) (7)
- New directions in perioperative management of locally advanced esophagogastric cancer. (2014) (7)
- Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure. (2006) (7)
- 198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (2020) (7)
- Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. (2014) (7)
- Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. (2015) (7)
- Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET-CT useful? (2013) (7)
- The AJCC staging system does not predict survival in patients receiving multimodality therapy for esophageal cancer (2005) (7)
- Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer (2009) (6)
- Commentary on Roviello et al., JSO‐2005‐00363.R1 (2006) (6)
- KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (6)
- Adjuvant therapy for noncolorectal cancers. (2001) (6)
- A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201. (2017) (6)
- Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors. (2016) (6)
- Neoadjuvant therapy for esophageal cancer: Who, when, and what? (2018) (6)
- GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2019) (6)
- 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two (2017) (6)
- Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. (2017) (6)
- Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. (2019) (6)
- A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer. (2012) (6)
- Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer. (2015) (5)
- Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers (2009) (5)
- Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2. (5)
- Just when you thought the fluorouracil debate was over: S-1 and gastric cancer. (2005) (5)
- Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction (2008) (5)
- Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS. (2019) (5)
- Irinotecan in esophageal cancer. (2003) (5)
- The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival. (2021) (5)
- Advances in the treatment of gastric cancer (2020) (5)
- 195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (2020) (5)
- Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). (2019) (5)
- Immunotherapy in esophagogastric cancer. (2021) (5)
- Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. (2012) (5)
- Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care. (2021) (5)
- Adenocarcinoma of the esophagus: controversies and consensus. (2017) (4)
- Pertuzumab plus Trastuzumab for (2019) (4)
- TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments. (2016) (4)
- Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study (2021) (4)
- Adjuvant postoperative therapy of gastrointestinal malignancies. (1994) (4)
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. (2019) (4)
- The role of radiation therapy in upper gastrointestinal cancers. (2017) (4)
- Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3. (2021) (4)
- Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. (2020) (4)
- Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade (2016) (3)
- Patient-Reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Esophageal Cancer Treated Without Surgery (2016) (3)
- Stage II Colon Cancer: To Treat or Not to Treat? (2008) (3)
- Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (3)
- Toxicity of chemotherapy for esophageal carcinoma. (1997) (3)
- Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study (2023) (3)
- Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS. (2019) (3)
- Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (3)
- Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) (2022) (3)
- 1032 Preliminary results of pre-operative 5-FU, low dose leucovorin (LV), and concurrent radiation therapy (RT) for resectable T3 rectal cancer (1996) (3)
- Abstract CT228: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer (2014) (3)
- OSI-774 in advanced esophageal cancer: a phase II study (2004) (3)
- Esophageal Cancer: Treatment (2014) (3)
- Cisplatin and irinotecan in upper gastrointestinal malignancies. (2001) (3)
- Barrett's esophagus: treatments of adenocarcinomas II (2011) (3)
- A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA). (2019) (2)
- Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization (2022) (2)
- Microsatellite Instability: A Biomarker in Gastric Cancer (2019) (2)
- An update in the nonendoscopic treatment of gastric cancer (2016) (2)
- Chemoradiotherapy in esophageal cancer: toxicity is in the eye of the beholder. (2009) (2)
- Survival and Patterns of Failure in Oligometastatic Esophagogastric Cancer (2020) (2)
- O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 (2020) (2)
- Dabrafenib plus Trametinib for (2020) (2)
- Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer (2022) (2)
- Is there a future for EGFR targeted agents in esophageal cancer? (2018) (2)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University (2015) (2)
- Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer. (2021) (2)
- OSI-774 in advanced esophageal cancer: a phase II study. (2004) (2)
- A nutritional management algorithm in older patients with locally advanced esophageal cancer. (2021) (2)
- Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE. (2020) (2)
- Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. (2020) (2)
- Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer? (2014) (2)
- Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS). (2018) (2)
- Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC). (2018) (2)
- Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy (2022) (1)
- Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma (2021) (1)
- Reduced-Dose Sorafenib for Hepatocellular Cancer (2017) (1)
- Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. (2018) (1)
- Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience. (2019) (1)
- Use of SUVmax to predict response to neoadjuvant chemoradiotherapy in patients with adenocarcinoma of the distal esophagus and GE Junction (2008) (1)
- The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer (2019) (1)
- Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. (2020) (1)
- Carcinomatosis in gastric cancer: the potential for cytoreductive surgery and intraperitoneal chemotherapy. (2019) (1)
- Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS). (2019) (1)
- Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome (2007) (1)
- Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma (2022) (1)
- Second-Line Chemotherapy for Gastric Cancer (2014) (1)
- Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors (2009) (1)
- CHEMOTHERAPY AND RADIOTHERAPY AS PRIMARY TREATMENT OF ESOPHAGEAL CANCER (2008) (1)
- Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. (2013) (1)
- Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer. (2022) (1)
- Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac. (2017) (1)
- PET-guided induction chemotherapy. (2007) (1)
- NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery. (2021) (1)
- Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). (2019) (1)
- Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma (2022) (1)
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023) (1)
- Emerging mAbs for the treatment of esophagogastric cancer (2015) (1)
- Laparoscopic vs. Open Gastrectomy in Gastric Cancer (2014) (1)
- Upper gastrointestinal malignancies: a new era in clinical colorectal cancer. (2009) (1)
- PET scan-directed chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): No benefit for salvage chemo in PET non-responders (PETnr). (2018) (1)
- Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer: Are we There Yet? (2018) (1)
- Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer. (2021) (1)
- Neoadjuvant and Adjuvant Treatment—Strategies and Clinical Trials—Western Perspective (2015) (1)
- Preface on Esophagus Cancer. (2017) (1)
- Nab-Paclitaxel plus Gemcitabine Improves Survival in Pancreatic Cancer (2013) (1)
- Lack of validation of lymphopenia as a prognostic factor in esophageal cancer chemoradiation (2018) (1)
- Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. (2023) (1)
- Selective Internal Radiation Therapy for Colorectal Cancer (2016) (1)
- TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. (2018) (1)
- Principles of Palliative/Best Supportive Care (2014) (1)
- Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer (2022) (1)
- Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy. (2019) (1)
- Is ERCC1 Expression a Useful Biomarker in Esophagogastric Cancer (2020) (0)
- Minimally Invasive Surgery for Esophageal Cancer (2019) (0)
- Waiting to Operate (2023) (0)
- ABSTRACTS Session 1: Esophageal/Gastric Cancer Chemotherapy and Radiotherapy are Necessary Preoperative Therapy (2012) (0)
- Lanreotide Effective for Nonfunctional Neuroendocrine Cancers (2014) (0)
- Three Months of CAPOX Acceptable in High-Risk Stage II Colon Cancer (2021) (0)
- Cetuximab for Colorectal Cancer Patients with (2011) (0)
- Survival Outcomes from Early-Onset Colorectal Cancer (2021) (0)
- The overexpression of EGFR and upregulation of the phosphatidylinositol 3-kinase Treatment Advance Relevant Study Results Early Gastric Cancer Advanced Gastric Cancer Early Esophageal Squamous Cell Cancer Advanced Hepatocellular Carcinoma Advanced Biliary Tract Cancer Examples of Major Advances in t (2011) (0)
- Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma. (2013) (0)
- Proton Beam vs. External Beam Radiotherapy for Locally Advanced Esophageal Cancer (2020) (0)
- ARTIST 2: Implications for Treatment of Node-Positive Gastric Cancer (2021) (0)
- PET-directed chemoradiation (CRT) with induction FOLFOX compared to induction carboplatin/paclitaxel (CP) in patients with locally advanced esophageal adenocarcinoma (EA). (2020) (0)
- Comparison of Trimodality Therapy to Chemoradiation Alone in a Large Cohort of Patients With Adenocarcinoma of the Esophagus (2015) (0)
- Radiotherapy Does Not Improve Outcome in Locally Advanced Pancreatic Cancer (2016) (0)
- Three Chemotherapy Drugs Not Better Than Two for Gastric Cancer (2014) (0)
- The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC (2019) (0)
- Long-Term Aspirin Use Reduces Risk for Gastrointestinal Cancer (2016) (0)
- Overuse of PET Scans in Lung and Esophageal Cancer (2016) (0)
- Adjuvant Therapy Improves Overall Survival in Gastric Cancer (2012) (0)
- Celecoxib Reduces Colorectal Polyp Formation but Increases Risk for Adverse Cardiovascular Events (2006) (0)
- MicroRNA Expression in Hepatocellular Cancer (2009) (0)
- SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers. (2022) (0)
- Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer (2017) (0)
- Second-Line Olaparib for Gastric Cancer (2018) (0)
- A Novel Prognostic Tool in Colon Cancer (2018) (0)
- GI Neuroendocrine Tumors Increasing in Incidence (2021) (0)
- Adding Cetuximab to Chemoradiotherapy Worsens Outcome in Esophageal Cancer (2013) (0)
- A New Therapy for Advanced Refractory Neuroendocrine Cancer (2017) (0)
- BRAF-Targeted Therapy for (2019) (0)
- A Second-Line Therapy for Cholangiocarcinoma Is Modestly Effective (2021) (0)
- ASCO 2021 — Gastrointestinal Cancer (2021) (0)
- Su1503 Dysphagia Relief and Adverse Events Associated With Fully Covered Evolution® Esophageal Stents in Malignant Esophageal Strictures: Does Size Matter? (2013) (0)
- Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers (2023) (0)
- Cancer Risk with the Lynch Syndrome (2015) (0)
- Metastatic Esophagogastric Cancer: Controversies, Consensus, and New Targets (2014) (0)
- 586 Response assessment classification: effect of multiple measurement criteria and parameters (2004) (0)
- New advances in the treatment of gastric cancer. (2004) (0)
- Adjuvant Therapy After Neoadjuvant Therapy for Resected Pancreatic Cancer (2020) (0)
- Adjuvant Chemotherapy After Preoperative Chemoradiation for Rectal Cancer (2018) (0)
- Genetic Determinants of Chemoradiation Response and Survival in Locally Advanced Esophageal Carcinoma Treated with Trimodality Therapy (2019) (0)
- Immunotherapy Shows Promise in MSI-High Colorectal Cancer (2015) (0)
- Regorafenib for Hepatocellular Carcinoma (2016) (0)
- Adding First-Line Nivolumab to Chemotherapy for Gastroesophageal Adenocarcinoma (2021) (0)
- Comparing Targeted Agents for Advanced Colorectal Cancer (2014) (0)
- FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer (2016) (0)
- Erlotinib Ineffective for Advanced Liver Cancer (2015) (0)
- Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study. (2021) (0)
- Bevacizumab Maintenance Therapy for Colorectal Cancer (2018) (0)
- Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer-Reply. (2018) (0)
- BRAF and KRAS Mutations Influence Prognosis in Stage III Colon Cancer (2016) (0)
- Sorting Out the Targeted-Agent Combinations for Colorectal Cancer (2008) (0)
- Preoperative therapy in esophageal cancer: controversy and consensus. (2010) (0)
- Chemotherapy for Gastric Cancer: Hold the Anthracycline and Spare the Taxane (2016) (0)
- Gemcitabine plus Capecitabine for Resected Pancreatic Cancer (2017) (0)
- Preoperative Chemoradiotherapy Improves Survival in Esophageal Cancer (2012) (0)
- FOLFIRINOX Beats Gemcitabine for Metastatic Pancreatic Cancer (2011) (0)
- Perioperative Chemotherapy for Resectable Gastric Cancer (2019) (0)
- Reduced-Intensity Chemotherapy in Older Patients with Gastroesophageal Cancer Does Not Compromise Efficacy (2021) (0)
- Lifestyle Risk Factors for Colon Cancer Recurrence (2013) (0)
- New developments in the treatment of esophageal cancer. (2002) (0)
- Cancer Prevention with Aspirin for Patients with Lynch Syndrome (2020) (0)
- Nanoliposomal Irinotecan Effective for Pancreatic Cancer (2015) (0)
- Testing for All (2014) (0)
- S-1 and Radiotherapy Effective in Older Patients with Esophageal Cancer (2021) (0)
- Lapatinib Fails to Improve Survival in HER2-Positive Gastric Cancer (2016) (0)
- Adjuvant Therapy for Pancreatic Cancer (2009) (0)
- The association of PET response with complete pathological response (CPR) and residual nodal disease (RND) after induction chemoradiotherapy (CRT) and resection of esophageal cancer: A review of 493 cases. (2009) (0)
- Camrelizumab plus Chemotherapy for Metastatic Esophageal Squamous Cell Cancer (2021) (0)
- FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma (2022) (0)
- First-Line Radiotherapy for Colorectal Cancer Liver Metastases (2017) (0)
- Can Capecitabine Replace 5-Fluorouracil for Locally Advanced Rectal Cancer? (2012) (0)
- GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study (2019) (0)
- Effect of Celecoxib Added to Standard Adjuvant Therapy for Colon Cancer (2021) (0)
- Three Months of CAPOX Emerges as an Adjuvant Standard for Stage III Colon Cancer (2021) (0)
- Hepatic Artery Embolization Alone or with Chemotherapy (2016) (0)
- ASCO 2008 Report: Gastrointestinal Cancer (2008) (0)
- Medicare Reimbursement for Colonoscopy (2007) (0)
- A Novel Cytotoxic Agent for Refractory Colorectal Cancer (2015) (0)
- Impact of pre-operative chemoradiotherapy on post-esophagectomy morbidity and mortality. (2006) (0)
- Second-Line Ramucirumab Improves Survival in Gastric Cancer (2013) (0)
- Gemcitabine vs. 5-FU After Resection of Pancreatic Cancer (2008) (0)
- Total Neoadjuvant Therapy in Rectal Cancer Increases Pathologic Complete Response (2021) (0)
- A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress. (2018) (0)
- Cetuximab for KRAS Wild-Type Colorectal Cancer (2009) (0)
- Laparoscopic vs. Open Resection for Colorectal Liver Metastases (2020) (0)
- Improved Regorafenib Dosing for Refractory Metastatic Colorectal Cancer (2019) (0)
- Nivolumab for Esophageal Squamous-Cell Cancer (2017) (0)
- Immune Checkpoint Inhibitor Therapy for Microsatellite Stable Colorectal Cancer (2020) (0)
- Whole B ody 18 FDG-PET a nd t he R esponse o f E sophageal Cancer t o I nduction T herapy: R esults o f a P rospective T rial (2003) (0)
- Pegvorhyaluronidase Alfa for Metastatic Pancreatic Cancer (2020) (0)
- All-RAS-Mutation Testing for Anti-EGFR Therapy (2015) (0)
- Are Chemotherapy Holidays an Option in Advanced Colorectal Cancer (2011) (0)
- Changing chemotherapy (C) with concurrent radiation (RT) followed by surgery after sub-optimal FDG-PET response to induction chemotherapy improves outcomes in locally advanced (LA) esophageal adenocarcinoma (EA). (2015) (0)
- Gastric Carcinomas Associated with (2006) (0)
- Systemic chemo (CTX) plus surgery and intraperitoneal (IP) CTX for patients (pts) with gastric cancer (GC) and peritoneal carcinomatosis (PC). (2019) (0)
- Long-Term Effects of Repeat Hepatectomy vs. Percutaneous Radiofrequency Ablation for Hepatocellular Cancer (2020) (0)
- Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma (2017) (0)
- Carboplatin plus Paclitaxel: A New Therapy Option for Anal Cancer (2020) (0)
- A Multigene Assay Is Prognostic in Stage II Colon Cancer (2012) (0)
- Combined modality therapy in locally advanced esophageal cancer (2015) (0)
- Adjuvant Chemotherapy Benefits MSI Stage III Colon Cancer (2021) (0)
- No Benefit for Adjuvant Radiation Therapy in Duodenal Cancer (2016) (0)
- Nivolumab for Chemotherapy-Refractory Gastric Cancer (2017) (0)
- HER2 a Potential Target in Colorectal Cancer (2016) (0)
- ASCO 2017 Report — Gastrointestinal Cancer (2017) (0)
- Molecular Markers and Stage II Colorectal Cancer (2011) (0)
- Preoperative Chemotherapy Without Radiotherapy in Rectal Cancer (2014) (0)
- Postoperative Pulmonary Complications after Neoadjuvant Chemoradiotherapy with IMRT for Esophageal Cancer (2010) (0)
- HER2 Is a Viable Target in Biliary Tract Cancer (2021) (0)
- Integrated safety findings with tesetaxel, an orally administered taxane, in patients (pts) with gastric, colon, breast, and nonsmall cell lung cancer: Phase II results. (2016) (0)
- Recurrence Score Validated for Stage II Colon Cancer (2013) (0)
- Impact of Lung and Heart Radiation Dose during Preoperative Chemoradiation on Overall Survival (OS) in Esophageal Cancer (EC) – Secondary Analysis of CALGB 80803 (Alliance) (2022) (0)
- Second-Line Chemotherapy Improves Survival in Patients with Advanced Gastric Cancer (2012) (0)
- Postoperative Carcinoembryonic Antigen Levels Are Prognostic in Colon Cancer (2018) (0)
- Liposome Encapsulated Irinotecan Is Active in Cholangiocarcinoma (2021) (0)
- ASCO 2016 Report — Gastrointestinal Cancer (2016) (0)
- Calcium Supplements Have Long-Term Benefit in Polyp Prevention (2007) (0)
- Irinotecan Adds No Benefit to Adjuvant Chemotherapy in Colon Cancer Patients (2007) (0)
- Adjuvant Gemcitabine Improves Long-Term Survival in Pancreatic Cancer (2013) (0)
- Second-Line Trastuzumab for HER2+ Advanced Gastric Cancer (2020) (0)
- Phase II trial of topoteean in patients with advanced renal cell carcinoma (1994) (0)
- ASCO 2013 Report — Gastrointestinal Cancer (2013) (0)
- Activity of gemcitabine/5-FU combination in refractory esophagogastric (EG) cancer. (2014) (0)
- Molecularly Matched Treatment for Pancreatic Cancer (2020) (0)
- Cetuximab Ineffective for Esophageal Cancer (2017) (0)
- Trastuzumab Deruxtecan Shows Promise in HER2-Positive Colorectal Cancer (2021) (0)
- The Role of Surgical Resection Following Primary Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma: A Decision Analysis (2011) (0)
- O-0005RTOG 0436: A PHASE III TRIAL OF CISPLATIN, PACLITAXEL AND RADIATION WITH OR WITHOUT CETUXIMAB IN THE NONOPERATIVE TREATMENT OF ESOPHAGEAL CANCER (2014) (0)
- Capecitabine Equivalent to Infusional 5-Fluorouracil for Rectal Cancer (2014) (0)
- Prognostic Factors in Colorectal Cancer (2011) (0)
- Diabetes mellitus (DM), serum glucose, and outcome in gastroesophageal (GE) cancer. (2009) (0)
- Racial Disparity in Colon Cancer Survival (2015) (0)
- Predictive Role of MSI-H in Colorectal Cancer Prognosis (2007) (0)
- Selective Internal Radiation vs. Sorafenib for Hepatocellular Carcinoma (2018) (0)
- Preoperative Therapy vs. Immediate Surgery for Locally Advanced Pancreatic Cancer (2020) (0)
- Avelumab Maintenance Therapy for Gastric Cancer (2021) (0)
- Cetuximab plus Bevacizumab-Based Chemotherapy in Colorectal Cancer (2009) (0)
- Mutation Increases Pancreatic Cancer Risk (2021) (0)
- Gemcitabine Remains the Chemotherapy Standard for Pancreatic Cancer (2009) (0)
- A New Therapy Targeting (2020) (0)
- Perioperative Chemotherapy Improves Survival in Gastroesophageal Cancer (2011) (0)
- Adjuvant Therapy with Bevacizumab for Colon Cancer (2011) (0)
- Revisiting VEGF Therapy for Metastatic Gastric Cancer (2013) (0)
- Phase I I T rial o f W eekly I rinotecan P lus C isplatin in A dvanced E sophageal C ancer (1999) (0)
- Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma - a phase ib/ii study. (2023) (0)
- Adding Radiation to Adjuvant Chemotherapy Fails to Improve Survival in Gastric Cancer (2015) (0)
- Adjuvant Sorafenib Fails to Improve Outcome in Hepatocellular Cancer (2015) (0)
- Cetuximab Improves Survival in Metastatic Colorectal Cancer (2014) (0)
- Pembrolizumab plus Lenvatinib for Gastric Cancer (2020) (0)
- Preoperative therapy in esophageal cancer. (2008) (0)
- Panitumumab Ineffective in G13D KRAS Mutant Colorectal Cancer (2013) (0)
- Colonoscopy and Left-Sided Colorectal Cancer (2009) (0)
- Circulating Tumor DNA as a Prognostic Biomarker in Colon Cancer (2019) (0)
- Cetuximab Therapy Is Inactive in Colorectal Cancer Patients with KRAS Mutations (2008) (0)
- PO-379 ENDOLUMINAL HIGH DOSE RATE BRACHYTHERAPY FOR EARLY STAGE AND RECURRENT ESOPHAGEAL CANCER (2012) (0)
- Relevance of Tumor Location in Colorectal Cancer (2017) (0)
- Cetuximab Fails to Improve Survival in Colon Cancer (2012) (0)
- Esophageal Cancer: Changing Epidemiology and the Role of Combined Modality Therapy. (2009) (0)
- Oxaliplatin for Rectal Cancer Is Not Effective (2011) (0)
- Adding Erlotinib to Gemcitabine Improves Survival in Pancreatic Cancer Patients (2007) (0)
- ASCO 2010 Report: Gastrointestinal Cancer (2010) (0)
- Total Neoadjuvant Therapy for Locally Advanced High-Risk Rectal Cancer (2021) (0)
- Optimal Collaborative Management of Patients With Esophagogastric Cancers (2017) (0)
- Octreotide Treatment for Neuroendocrine Tumors (2009) (0)
- Cetuximab Improves Survival in Patients with Refractory Colorectal Cancer (2007) (0)
- ASCO 2020 Report — Gastrointestinal Cancer (2020) (0)
- Gemcitabine plus Cisplatin in Patients with Advanced Cholangiocarcinoma (2010) (0)
- Lapatinib Does Not Improve Survival in HER2-Positive Gastroesophageal Cancer (2015) (0)
- Transcatheter Arterial Catheter Embolization for Hepatocellular Cancer (2013) (0)
- Postoperative Adjuvant Therapy After Resection of Regionally Advanced Esophageal Cancer (2014) (0)
- Combination Chemotherapy for Metastatic Pancreatic Cancer (2010) (0)
- Surufatinib for Advanced Pancreatic Neuroendocrine Cancer (2020) (0)
- The 2021 Gastrointestinal Cancers Symposium (2021) (0)
- Higher-Dose Radiotherapy Adds No Benefit in Esophageal Cancer (2021) (0)
- ASCO 2014 Report — Gastrointestinal Cancer (2014) (0)
- Ramucirumab Improves Survival in Gastric Cancer (2014) (0)
- Response assessment parameters in esophageal cancer - conventional and novel techniques. (2004) (0)
- Nivolumab plus Ipilimumab for MSI-High/dMMR-Deficient Colorectal Cancer (2018) (0)
- ASO Visual Abstract: Association of Obesity with Worse Operative and Oncologic Outcomes Among Patients Undergoing Gastric Cancer Resection (2021) (0)
- Oral Adjuvant Chemotherapy with S-1 Lengthens Survival in Gastric Cancer Patients (2007) (0)
- Ninth Annual ISGIO Meeting. (2012) (0)
- Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer (2019) (0)
- Prognostic Significance Of FDG-PET Metrics In Esophageal Squamous Cell Carcinoma (2014) (0)
- ASCO 2015 Report — Gastrointestinal Cancer (2015) (0)
- Targeting Inflammatory Response in Pancreatic Cancer (2015) (0)
- Maintenance Therapy for (2019) (0)
- Second-Line Panitumumab for Colorectal Cancer (2011) (0)
- Adjuvant Therapy for Gallbladder Cancer (2016) (0)
- Adjuvant Bevacizumab for Colorectal Cancer (2016) (0)
- Preoperative Chemotherapy Is Feasible in Pancreatic Cancer (2021) (0)
- Pembrolizumab for Refractory Gastric or Gastroesophageal Junction Cancer (2018) (0)
- Is It Safe to Discontinue Imatinib for Advanced Gastrointestinal Stromal Tumors (2010) (0)
- How I Treat Patients with Esophageal Cancer (2014) (0)
- Hyperthermic Intraperitoneal Chemotherapy Fails to Improve Colon Cancer Outcomes (2021) (0)
- Good News and Bad News About Colonic Polyps and Prevention of Colon Cancer: The Bad News (2007) (0)
- Esophageal cancer and barrett’s esophagus Esophageal cancer and barrett’s esophagus (2015) (0)
- Adjuvant S-1 for Resected Pancreatic Cancer (2016) (0)
- Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer (2019) (0)
- Esophageal cancer and barrett's esophagus: Sharma/Esophageal cancer and barrett's esophagus (2015) (0)
- How Do I Treat… …a Patient with Locally Advanced Esophageal Cancer? (2012) (0)
- FOLFIRINOX Not Better Than Gemcitabine-Cisplatin in Biliary Cancer (2021) (0)
- Options for the Adjuvant Treatment of Colon Cancer (2007) (0)
- Hope for Patients with Gastric Cancer (2006) (0)
- Laparoscopic Resection Equals Open Surgery for Gastric Cancer (2016) (0)
- Trial Questions Role of Resection of the Primary Tumor in Metastatic Colorectal Cancer (2021) (0)
- Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study (2019) (0)
- Postoperative Chemoradiotherapy for Gastric Cancer (2018) (0)
- Adjuvant FOLFIRINOX vs. Gemcitabine for Pancreatic Cancer (2019) (0)
- Intensive Follow-Up Fails to Yield Clear Benefit in Colorectal Cancer (2014) (0)
- Sorafenib Lengthens Survival in Patients with Advanced Hepatocellular Cancer (2008) (0)
- Cetuximab vs. Bevacizumab for (2017) (0)
- 1227P Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC) (2022) (0)
- Are Targeted Agents for Colorectal Cancer Cost Effective (2015) (0)
- Docetaxel Combination Chemotherapy Lengthens Survival in Gastric Cancer Patients (2006) (0)
- Long-Term Follow-Up Supports Watch and Wait in Rectal Cancer (2021) (0)
- Capecitabine vs. Fluorouracil for Colorectal Cancer (2009) (0)
- Second-Line Pembrolizumab vs. Chemotherapy for Advanced Esophageal Cancer (2020) (0)
- First-Line Panitumumab for Colorectal Cancer (2011) (0)
- ASCO 2009 Report: Gastrointestinal Cancer (2009) (0)
- Cetuximab Fails to Improve Colorectal Cancer Outcomes (2012) (0)
- When to Assess Treatment Response in Anal Cancer (2017) (0)
- Intensity-modulated radiotherapy for esophageal cancer: Analysis of toxicity and outcomes. (2010) (0)
- EGFR-Inhibitor Therapy for non-V600E (2019) (0)
- Bevacizumab plus Atezolizumab for Advanced Hepatocellular Cancer (2020) (0)
- Benefit of Aspirin to Reduce Colon Cancer Risk Is Age and Duration Dependent (2021) (0)
- Ramucirumab Effective in Colorectal Cancer (2015) (0)
- Avoidance of Surgery in Select Patients with Rectal Cancer (2016) (0)
- Preemptive Skin Care Before Panitumumab Therapy (2010) (0)
- Yttrium Radioembolization with Second-Line Chemotherapy in CRC (2021) (0)
- Second-Line Everolimus Fails to Improve Survival in Hepatocellular Cancer (2014) (0)
- FOLFOXIRI for Metastatic Colorectal Cancer (2014) (0)
- Pembrolizumab for Microsatellite-Instability–High Advanced Colorectal Cancer (2020) (0)
- Stage II gastric cancer: 1 year of S-1 remains standard of care. (2019) (0)
- Pembrolizumab Has Promising Activity in PD-L1–Positive Gastric Cancer (2016) (0)
- Preoperative Chemoradiotherapy for Esophageal Cancer (2009) (0)
- Maintenance Capecitabine Improved Progression-Free but Not Overall Survival in Metastatic Colorectal Cancer (2021) (0)
- Panitumumab Fails to Improve Outcome in Esophagogastric Cancer (2013) (0)
- Induction Chemotherapy and 5-FU/Cisplatin Fail to Improve Outcomes in Anal Cancer (2008) (0)
- Docetaxel Fails to Improve Survival as Part of First-Line Chemotherapy in Gastric Cancer (2019) (0)
- Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. (2023) (0)
- Preoperative Therapy in Patients with Esophageal Cancer (2007) (0)
- BRAF Mutation and Treatment Resistance in Colorectal Cancer Patients (2009) (0)
- Trastuzumab Deruxtecan for Previously Treated HER2+ Gastric Cancer (2020) (0)
- Duration of Adjuvant Chemotherapy in Colon Cancer: Current Standards and New Updates (2019) (0)
- First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma (2018) (0)
- Second-Line Pembrolizumab vs. Paclitaxel for Advanced Esophagogastric Cancer (2018) (0)
- Nivolumab for Advanced Hepatocellular Carcinoma (2017) (0)
- Adjuvant Gemcitabine and Oxaliplatin for Resected Biliary Cancer (2019) (0)
- Regorafenib Improves Survival in Refractory Colorectal Cancer (2012) (0)
- Definitive Chemoradiation for Adenocarcinoma of the Esophagus and Gastroesophageal Junction (2012) (0)
- Hypothermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies—A Relic of the Past or Useful Tool for Today? (2019) (0)
- Longer Imatinib Therapy Effective for Gastrointestinal Stromal Tumors (2012) (0)
- Updates in Esophagogastric Cancer. (2017) (0)
- Post-Treatment ANC is Predictive of Poorer Overall Survival and Disease-Free Survival in Esophageal Cancer Patients after Tri-Modality Therapy (2019) (0)
- Differences in genomic profiles of gastric adenocarcinoma in the US and Japan. (2023) (0)
- Vitamin D Cancer Therapy (2019) (0)
- Calcium and Magnesium Fail to Prevent Oxaliplatin Neuropathy (2013) (0)
- Pemigatinib for Advanced Cholangiocarcinoma (2020) (0)
- Neoadjuvant therapy of esophageal cancer. (1997) (0)
- Outcomes after chemoradiation alone for adenocarcinoma of the esophagus and gastroesophageal junction. (2015) (0)
- Capecitabine and Oxaliplatin Are Effective in Advanced Gastric Cancer (2008) (0)
- Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection (2021) (0)
- FDG-PET scan after induction chemotherapy for esophageal squamous cell cancer (ESCC) to predict for outcomes after chemoradiation (chemoRT) and to guide salvage chemotherapy during RT. (2014) (0)
- Stage IV small bowel carcinoma mimicking advanced ovarian cancer. (2009) (0)
- Shorter-Duration Adjuvant Therapy for High-Risk Stage II Colorectal Cancer (2020) (0)
- Four Subtypes Emerge from Molecular Characterization of Gastric Cancer (2014) (0)
- Editorial on a Phase I Study on Combined Modality Therapy in Esophageal Cancer (2004) (0)
- PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria. (2020) (0)
- Cetuximab Ineffective for Esophagogastric Cancer (2013) (0)
- Panitumumab Ineffective for Colorectal Cancers with Rare (2013) (0)
- Trifluridine/Tipiracil for Advanced Chemotherapy-Refractory Gastric Cancer (2018) (0)
- The 2019 Gastrointestinal Cancers Symposium (2019) (0)
- Nivolumab plus Ipilimumab for Previously Treated Patients with Advanced Hepatocellular Carcinoma (2020) (0)
- Expression of TS and p53 Are Not Prognostic in Early-Stage Colorectal Cancer (2007) (0)
- Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). (2018) (0)
- Minimal residual local disease predicts improved survival after chemoradiotherapy in patients with squamous cell carcinoma of the esophagus (2007) (0)
- Capecitabine for Stage III Colon Cancer (2011) (0)
- Maintenance Therapy for Metastatic Colorectal Cancer (2015) (0)
- Cabozantinib for Advanced Hepatocellular Cancer (2018) (0)
- Laparoscopic Is Noninferior to Open Distal Gastrectomy for Survival in Gastric Cancer (2019) (0)
- Gastrectomy Fails to Improve Survival in Metastatic Gastric Cancer (2016) (0)
- The COX-2 Inhibitor Rofecoxib Fails to Reduce Colorectal Cancer Recurrence (2013) (0)
- Cancer of the Esophagus (2020) (0)
- Impact of Lymph Node Status on Survival in Gastric Cancer (2016) (0)
- Long-Term Outcomes with TACE plus RFA for Hepatocellular Cancers (2021) (0)
- Second-Line Chemotherapy for Pancreatic Cancer (2016) (0)
- Intensive Surveillance for Colorectal Cancer (2018) (0)
- TDM-1 for HER2-Positive Esophagogastric Cancer (2017) (0)
- Capecitabine vs. Gemcitabine for Pancreatic Cancer (2013) (0)
- Combination Chemotherapy for Advanced Pancreatic Cancer (2010) (0)
- Survival Improvement with Adjuvant Gemcitabine in Patients with Pancreatic Cancer (2007) (0)
- Regorafenib Active in Refractory Gastrointestinal Stromal Tumors (2012) (0)
- Adjuvant Capecitabine After Biliary Cancer Resection (2019) (0)
- The 2020 Gastrointestinal Cancers Symposium (2020) (0)
- Adjuvant Chemoradiotherapy After Curative Resection for Gastric Cancer (2017) (0)
- ASCO 2019 Report — Gastrointestinal Cancer (2019) (0)
- Pancreatic Neuroendocrine Cancer: Renewed Hope for Treatment (2011) (0)
- A Possible Mechanism of Hypothyroidism in Gastrointestinal Stromal Tumors (2014) (0)
- HER2 status of gastric and gastroesophageal cancer (GC) patients assessed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and high-resolution array comparative genomic hybridization (aCGH). (2010) (0)
- How Do I Treat Patients with Locally Advanced Gastric Cancer (2013) (0)
- Radiotherapy for Node-Positive Gastric Cancer (2012) (0)
- Advances in Esophageal and Gastric Cancer (2017) (0)
- Delay to Surgery May Harm Rectal Cancer Nonresponders to Neoadjuvant Therapy (2021) (0)
- Aflibercept Improves Survival in Metastatic Colorectal Cancer (2012) (0)
- Pembrolizumab Added to Chemotherapy Improves Survival in Advanced Esophageal Cancer (2021) (0)
- Bevacizumab Falls Short in Treating Advanced Gastric Cancer (2011) (0)
- Variable penetrance of CDH1 mutation diffuse gastric cancer: A genomic analysis. (2013) (0)
- Smoking Clearly Linked to Esophageal Adenocarcinoma (2010) (0)
- Chemotherapy for Advanced Hepatocellular Cancer (2013) (0)
- Adjuvant Therapies for Older Colon Cancer Patients (2013) (0)
- First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric cancer (2021) (0)
- Risk for Esophageal Cancer in Patients with Gastroesophageal Reflux (2018) (0)
- Adjuvant Bevacizumab for Operable Gastroesophageal Cancer (2017) (0)
- Everolimus Fails to Improve Survival in Refractory Gastric Cancer (2013) (0)
- Cetuximab Fails to Extend OS in Locally Advanced Esophageal Cancer (2014) (0)
- Linifanib Fails to Improve Survival in Hepatocellular Cancer (2015) (0)
- Shorter Duration Adjuvant Therapy for Stage III Colon Cancer (2018) (0)
- ASCO 2018 Report — Gastrointestinal Cancer (2018) (0)
- Tenth Annual ISGIO Meeting. (2013) (0)
- Adjuvant Nivolumab in Esophageal Cancer (2021) (0)
- Hybrid Minimally Invasive Esophagectomy Does Not Compromise Long-Term Survival (2021) (0)
- Second-Line Ramucirumab for Advanced Hepatocellular Cancer (2019) (0)
- A Novel Risk Factor for Pancreatic Cancer (2013) (0)
- Surrogate Markers: The Role of Positron Emission Tomography Scanning (2013) (0)
- Retrospective review of subsequent treatments (tx) for esophagogastric adenocarcinomas (EGA) refractory to FOLFOX. (2017) (0)
- Dietary Habits Could Affect Risk for Colorectal Cancer Recurrence (2007) (0)
- First-Line Pembrolizumab for Advanced Gastric Cancer (2020) (0)
- Adding cisplatin to split course radiotherapy increases progression-free survival compared to radiotherapy alone in people with inoperable squamous cell esophageal cancer (2001) (0)
- The Current and Future Management of Gastric Cancer With David H. Ilson, MD, PhD (2017) (0)
- Everolimus Improves Progression-Free Survival in Carcinoid Tumors (2016) (0)
- Ripretinib for Gastrointestinal Stromal Tumors (2020) (0)
- An Argument for Colorectal Cancer Mismatch Repair Testing (2013) (0)
- The 2018 Gastrointestinal Cancers Symposium (2018) (0)
- Promising Results for Olaparib in Gastric Cancer (2015) (0)
- Aspirin Lowers Risk for (2013) (0)
- Trastuzumab for HER2-Positive Gastroesophageal Cancer (2010) (0)
- Next-generation sequencing to identify predictors of survival after trimodality therapy for esophageal cancer. (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David H. Ilson?
David H. Ilson is affiliated with the following schools:
